Ligand Pharmaceuticals LGND Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's cumulative cost basis?
- Ligand Pharmaceuticals (LGND) reported cumulative cost basis of $607.54M in Q1 2026.
- How has Ligand Pharmaceuticals's cumulative cost basis changed year-over-year?
- Ligand Pharmaceuticals's cumulative cost basis increased by 349.4% year-over-year, from $135.18M to $607.54M.
- What is the long-term trend for Ligand Pharmaceuticals's cumulative cost basis?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's cumulative cost basis has grown at a 9.2% compound annual growth rate (CAGR), from $324.57M to $503.29M.